Abstract: A vehicle radar system (3) which, for each one of a plurality of radar cycles, is arranged to, provide a measured azimuth angle (?m) and radial velocity (vdm) for a first plurality of detections (9, 20). For each one of the plurality of radar cycles, the radar system (3) is arranged to select one of these detections for each one of two velocity components (vx, vy) in a set of components (vx, vy, ax, ay; a) to be determined; select one detection from a second plurality of detections (9, 20) for each one of at least one corresponding acceleration component (ax, ay; a); calculate the components (vx, vy, ax, ay; a) for the selected detections; determine a calculated radial velocity (vdc) for each one of at least a part of the other detections in the first plurality of detections (9, 20) using the calculated components (vx, vy, ax, ay; a); determine an error between each calculated and measured radial velocity (vdc, vdm); and determine the number of inliers.

Abstract: The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 50 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.

Abstract: Antigen binding polypeptide specifically binding to ?/? T cell receptor (TCR)/cluster of differentiation 3 (CD3) complex. Nucleic acid containing a sequence encoding for the antigen binding polypeptide or a vector containing the nucleic acid. Recombinant host cells containing the antigen binding polypeptide, and pharmaceutical compositions containing the antigen binding polypeptide, the nucleic acid, the vector, and/or the host cell. Use of the antigen binding polypeptide, the nucleic acid, the vector, the host cell, or the pharmaceutical composition in medicine, in particular for use in the diagnosis, prevention, and/or treatment of a proliferative disease. Methods for improving or maintaining the binding and/or improving the stability of the antigen binding polypeptides. Methods for detecting, determining or enriching T cells expressing the ?/? TCR/CD3 complex.

Abstract: A tool system for mounting an elastic sleeve includes a holdout tube supporting the elastic sleeve prior to and during mounting, the holdout tube having a longitudinal axis, an interface element movable along the longitudinal axis and transferring pressure onto the elastic sleeve to push the elastic sleeve off the holdout tube during mounting, and an actuation lever engaging the holdout tube at a fulcrum region of the actuation lever. The actuation lever has a pair of load arms partly encompassing the holdout tube. A load region is arranged at a peripheral end of each of the load arms. The actuation lever actuates the interface element by pressing the load regions of the actuation lever against the interface element.

Abstract: The present invention relates to a bispecific polypeptide molecule comprising a first polypeptide chain and a second polypeptide chain providing a binding region derived from a T cell receptor (TCR) being specific for a major histocompatibility complex (MHC)-associated peptide epitope, and a binding region derived from an antibody capable of recruiting human immune effector cells by specifically binding to a surface antigen of said cells, as well as methods of making the bispecific polypeptide molecule, and uses thereof.

Abstract: The present invention relates to a bispecific polypeptide molecule comprising a first polypeptide chain and a second polypeptide chain providing a binding region derived from a T cell receptor (TCR) being specific for a major histocompatibility complex (MHC)-associated viral peptide epitope, and a binding region derived from an antibody capable of recruiting human immune effector cells by specifically binding to a surface antigen of said cells, as well as methods of making the bispecific polypeptide molecule, and uses thereof.

Abstract: The present invention relates to a cytotoxic agent for the prophylaxis and/or treatment of a viral infection which is configured for the selective binding to a membrane receptor of virus-infected T lymphocytes, a pharmaceutical composition containing said cytotoxic agent, the use of the cytotoxic agent for the prophylaxis and/or treatment of viral infections, a method of finding cytotoxic agents, the use of a membrane receptor of virus-infected T lymphocytes which is overexpressed in comparison to non-infected T lymphocytes for the diagnosis of a viral infection.

Abstract: A vehicle radar system (3) and related method including at least one transceiver arrangement (7) arranged to generate and transmit radar signals (4), and to receive reflected radar signals (5). The radar signals form a plurality of sensing sectors or sensing bins (8a-8g), that together form a transceiver coverage (9), For each sensing bin (8a-8g) the radar system (3) is arranged to obtain a target angle (?) and a target range (r) to possible target objects (10a-10j). The radar system (3) is further arranged to determine an unoccupied domain border (11) and a corresponding unoccupied domain (12) for the radar transceiver coverage (9).

Abstract: The present disclosure relates to a bearing arrangement for supporting a shaft, in particular a shaft of a gearing mechanism for an electromechanical brake booster, having: at least one bearing, a shaft, which is at least section-wise accommodated in the at least one bearing and has a protruding, rounded region on at least one of its axial end surfaces, at least one spring element, that engages the protruding, rounded region in order to prestress the shaft in the axial direction.

Abstract: A vehicle environment detection system (2) that includes at least one radar sensor arrangement (3) and at least one processing unit (4), where the radar sensor arrangement (3) is arranged to detect at least two radar detections (9, 10, 11) during at least two radar cycles. For each radar cycle, the processing unit (4) generates a detection list ({Dit}t=t0, . . . ,t0?N) including range (ri), azimuth angle (?i) and Doppler velocity (vi) for each of the radar detections (9, 10, 11). The processing unit (4) is further arranged to aggregate and store detection lists ({Dit}t=t0, . . . ,t0?N) from the radar cycles in a detection memory (12), and then to group the radar detections (9, 10, 11) in the detection lists ({Dit}t=t0, . . . ,t0?N) into consistently moving motion subsets (40, 41, 42) in a segmentation procedure. Each motion subset (40, 41, 42) corresponds to a certain target object (6, 7, 8).

Abstract: The present invention relates to a cytotoxic agent for the prophylaxis and/or treatment of a viral infection which is configured for the selective binding to a membrane receptor of virus-infected T lymphocytes, a pharmaceutical composition containing said cytotoxic agent, the use of the cytotoxic agent for the prophylaxis and/or treatment of viral infections, a method of finding cytotoxic agents, the use of a membrane receptor of virus-infected T lymphocytes which is overexpressed in comparison to non-infected T lymphocytes for the diagnosis of a viral infection.

Abstract: The current invention concerns a method for preparing an emulsion comprising the steps: mixing a first phase and a second phase in a layer multiplier to produce a multilayered fluid structure, and collapsing said multilayered fluid structure, thereby dispersing the second phase in the first phase creating an emulsion. The current invention relates to a method for producing dispersions. The current invention also concerns the emulsions produced by said method. The current method also relates to polymer emulsions, particularly polyisobutene emulsions with a high content of polyisobutene.

Abstract: An electrically actuatable operating unit (106) for a motor vehicle brake comprises a housing body (122) which is arranged so as to be displaceable in a braking direction for operation of the motor vehicle brake, a recess (150) formed in the housing body (122), wherein the recess (150) is delimited at one longitudinal end by a contact shoulder (172), a through-opening (158) delimited by the contact shoulder (172), an operating member (124) which is arranged in the recess (150) so as to be displaceable for operation of the motor vehicle brake and projects through the through-opening (158) of the contact shoulder (172), wherein the operating member (124) can be arranged in a force-transmitting manner between a brake pedal and the motor vehicle brake (400).

Abstract: A bushing adapter comprises an insert having a bore extending through the insert along a length direction of the insert and a fastening member extending through the bore. The insert is configured to be attached to a bushing conductor of a bushing. The fastening member has an operating portion positioned outside of the bore at a bushing internal end of the fastening member and a fastening portion positioned outside of the bore at a bushing external end of the fastening member.

Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel engineered T cell receptor (TCR) based molecules which are selective and specific for the tumor expressing antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

Abstract: A bushing comprises an insulating body having a first body end portion, a second body end portion, and a body center portion connecting the first body end portion and the second body end portion, and a bushing conductor coaxially extending within and mechanically coupled to the insulating body. The bushing conductor includes a first connecting portion having a first end face at the first body end portion, a second connecting portion having a second end face at the second body end portion, and a center portion electrically and mechanically connecting the first connecting portion and the second connecting portion. The first connecting portion is elastically deformable with respect to the first body end portion along a radial direction and/or the second connecting portion is elastically deformable with respect to the second body end portion along the radial direction.

Abstract: The disclosed electromechanical brake booster for a vehicle brake system comprises a driving arrangement for driving at least one actuation device designed to actuate a brake cylinder. The driving arrangement includes at least one electric motor and a gear mechanism for coupling the electric motor to the at least one actuation device. The gear mechanism comprises at least one first spur gear and at least one second spur gear, the electric motor driving the first spur gear directly and the second gear via at least one intermediate gear.

Abstract: The present invention relates to a method for the characterization of peptide:MHC binding polypeptides, e.g. by mass spectrometry and an analysis of the recognized peptide space, i.e. in order to identify peptides that can be bound in the context of their presentation by MHC, and those who cannot be bound.

Abstract: The present invention concerns bispecific antigen binding proteins directed against MHC presented target antigens (TA). The invention in particular provides bispecific antigen binding proteins comprising at least two antigen binding sites (A and B), wherein the antigen binding site A binds to CD3 and the antigen binding site B binds to a target antigenic (TA) peptide/MHC complex. The bispecific antigen binding proteins of the invention comprise, in particular, the CDRs of the VL and VH domains of novel engineered anti-CD3 antibodies having a reduced affinity. The bispecific antigen binding proteins of the invention are of use for the diagnosis, treatment and prevention of TA associated diseases, such as tumor-associated antigen (TAA) expressing cancerous diseases.

Abstract: The present invention concerns antigen binding proteins specifically binding melanoma associated antigen A (MAGE-A) protein-derived antigens. The invention in particular provides antigen binding proteins which specifically bind to the MAGE-A antigenic peptide comprising or consisting of SEQ ID NO: 1 in a complex with a major histocombatibility (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said MAGE-A peptide/MHC complex. The antigen binding proteins of the invention are of use for the diagnosis, treatment and prevention of MAGE-A expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.